Top 10 Asthma Drugs in the World

Top 10 Asthma Drugs in the World

The asthma market is highly saturated with relatively efficacious standard therapies and the COPD market is also highly saturated with therapies that help to prevent exacerbations of the disease. However, there is a considerable unmet need for innovative new therapies for severe asthmatics who do not respond to the current standards of care and treatments which can reverse the progression of COPD. This report assesses first-in-class innovation across asthma and COPD pipelines.

1 . World's Top 10 Asthma Medicines based on their 2018 Revenue are:

  1. Seretide/ Advair by GlaxoSmithKline PLC : USD 3.221 billion
  2. Ellipta by GlaxoSmithKline PLC : USD 2.725 billion
  3. Symbicort by AstraZeneca PLC : USD 2.561 billion
  4. Xolair by Roche Holding AG / Novartis AG : USD 1.912 billion
  5. Pulmicort by AstraZeneca PLC : USD 1.286 billion
  6. Ventolin by GlaxoSmithKline PLC : USD 0.980 billion
  7. Flixotide/ Flovent by GlaxoSmithKline PLC : USD 0.791 billion
  8. Nucala/ Mepolizumab by GlaxoSmithKline PLC : USD 0.749 billion
  9. Singulair by Merck & Co., Inc. : USD 0.708 billion
  10. Fasenra by AstraZeneca PLC : USD 0.297 billion
Top 10 Asthma Drugs in the World
 

2 . Top 10 Asthma Drugs in the World

1. Seretide / Advair

Advair is the world's top asthma drug by revenue manufactured by GlaxoSmithKline PLC. In FY 2018 it had total global sales of USD 3.221 billion. Advair is available in two ways Advair Diskus and Advair HFA. ADVAIR DISKUS is a prescription medicine used to treat asthma in patients 4 years and older. ADVAIR HFA is a prescription medicine used to treat asthma in patients 12 years and older. ADVAIR is not for adults and children with asthma who are well controlled with an asthma control medicine, such as an inhaled corticosteroid (ICS) medicine. ADVAIR is for adults and children with asthma who need both an ICS and long-acting beta2-adrenergic agonist (LABA) medicine. ADVAIR DISKUS 250/50 is a twice-daily prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups. ADVAIR HFA is not approved for the treatment of COPD.

Following are the safety information for Advair:

  • Advair cannot be used to treat sudden breathing problems from asthma or COPD.
  • ADVAIR DISKUS cannot be used if someone has a severe allergy to milk proteins.
  • Without doctors, prescription Advair should not be used.
  • Advair should not be mixed with other medicines that contain LABA for any reason.

Side effects of Advair includes: fungal infection in your mouth or throat (thrush), reduced adrenal function, pneumonia, weakened immune system and increased chance of getting infections (immunosuppression), effects on heart, bone thinning or weakness, slowed growth in children, eye problems, serious allergic reactions, changes in laboratory blood values etc.

2. Ellipta

Under Ellipta group of drugs GlaxoSmithKline PLC has the following medicines:

  • Anoro Ellipta – FY 2018 revenue was USD 0.663 billion. ANORO contains 2 medicines that work together to significantly improve lung function all day and all night, but the results may vary. Once-daily ANORO is a prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing. ANORO is not used to treat sudden COPD symptoms and won't replace a rescue inhaler. ANORO is not for asthma. Some side effects of Anoro are: allergy like rash, hives, swelling of face, breathing problems, effect on heart & nervous system etc.
  • Arnuity Ellipta – FY 2018 revenue was USD 0.059 billion. ARNUITY ELLIPTA is a prescription inhaled corticosteroid (ICS) medicine taken as 1 inhalation, once daily, for the control and prevention of asthma in adults and children aged 5 years and older. ARNUITY helps to prevent and control symptoms of asthma, and thus it is not used to relieve sudden breathing problems.
  • Incruse Ellipta – FY 2018 revenue was USD 0.378 billion. Once-daily INCRUSE is a prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing. >Relvar/ Breo Ellipta – FY 2018 revenue was USD 1.448 billion. BREO ELLIPTA is indicated for the once-daily treatment of asthma in patients aged 18 years and older. BREO ELLIPTA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA). BREO ELLIPTA 100/25 should be administered as 1 inhalation once daily. The maximum recommended dosage is 1 inhalation of BREO ELLIPTA 100/25 once daily, theonly strength indicated for the treatment of COPD.
  • Trelegy Ellipta – FY 2018 revenue was USD 0.207 billion. Once-daily TRELEGY is a prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups. TRELEGY is not used to relieve sudden breathing problems and won't replace a rescue inhaler. TRELEGY is not for asthma.
 
Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

Gain Insights on 266 and 161 Pipeline Programs in Active Development for Asthma and COPD, Respectively

 

3. Symbicort

Symbicort is the third best-selling asthma drug by revenue manufactured by AstraZeneca PLC. In FY 2018 it had total global sales of USD 2.561 billion. This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).

It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta-agonists. It works by opening airways in the lungs to make breathing easier. SYMBICORT is for the treatment of asthma in patients 6 years and older whose asthma is not well-controlled with an asthma-control medicine such as an inhaled corticosteroid (ICS) or whose asthma warrants treatment with both an ICS and a long-acting beta2-adrenergic agonist (LABA).

Some of the side-effects of Symbicort are:

  • Using too much of a LABA medicine may cause chest pain, fast and irregular heartbeat, tremor, increased blood pressure, headache or nervousness
  • Fungal infection in your mouth or throat (thrush)
  • Pneumonia and other lower respiratory tract infections
  • Adrenal insufficiency
  • Increased wheezing right after taking SYMBICORT etc.
 

4. Xolair

Xolair is fourth best-selling asthma drug by revenue and manufactured by Roche Holding AG and Novartis AG. In FY 2018 it had total global sales of USD 1.912 billion. Omalizumab, sold under the trade name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria. Moderate to severe persistent allergic asthma in patients 6 years of age or older not controlled by inhaled corticosteroids. XOLAIR is not used to treat other allergic conditions, acute bronchospasm or status asthmaticus. XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks.

Some of the side effects of Xolair are:

  • Inflammation of blood vessels
  • Fever, muscle aches, and rash
  • Parasitic infection
  • Heart and circulation problems etc.

5. Pulmicort

Pulmicort by its revenue is the fifth best-selling asthma drug manufactured by AstraZeneca PLC. In FY 2018 it had total global sales of USD 1.286 billion. Pulmicort contains budesonide, a corticosteroid that prevents the release of substances in the body that cause inflammation. Pulmicort is used to prevent asthma attacks, which is caused by wheezing and shortness of breath caused by asthma.

This medication belongs to a class of drugs known as corticosteroids. It works directly in the lungs to make breathing easier by reducing the irritation and swelling of the airways. Pulmicort should be exactly used as it is prescribed by the doctor. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, one must use their quick-relief inhaler as prescribed.

6. Ventolin

Ventolin HFA by its revenue is the sixth best-selling asthma drug manufactured by GlaxoSmithKline PLC. In FY 2018 it had total global sales of USD 0.98 billion. Ventolin (albuterol) is a bronchodilator that relaxes muscles in the airways and increases airflow to the lungs. Ventolin HFA is used to treat or prevent bronchospasm, or narrowing of the airways in the lungs, in people with asthma or certain types of chronic obstructive pulmonary disease (COPD). It is also used to prevent exercise-induced bronchospasm.

Some of the safety information related to use of Ventolin HFA:

  • Not to use Ventolin HFA if someone is allergic to albuterol sulfate.
  • Proper knowledge of dose on how to use Ventolin HFA.
  • To get medical help right away if Ventolin HFA is no longer helpful in controlling the symptoms (like wheezing and trouble breathing).

Some of the side effects of Ventolin HFA:

  • Worsening trouble breathing, coughing, and wheezing (paradoxical bronchospasm)
  • Heart problems, including faster heart rate and higher blood pressure.
  • Possible death in people with asthma who use too much VENTOLIN HFA.
  • Serious allergic reactions etc.

7. Flixotide/ Flovent

Flixotide/ Flovent by its revenue is the seventh best-selling asthma drug manufactured by GlaxoSmithKline PLC. In FY 2018 it had total global sales of USD 0.791 billion. FLOVENT is a prescription inhaled corticosteroid medicine for the long-term treatment of asthma in people aged 4 years and older. FLOVENT is not used to relieve sudden breathing problems and won't replace a rescue inhaler.

8. Nucala/ Mepolizumab

Nucala by its revenue is the eighth best-selling asthma drug manufactured by GlaxoSmithKline PLC. In FY 2018 it had total global sales of USD 0.749 billion. NUCALA is an add-on, prescription maintenance treatment for patients 12 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. It's an injection that one gets in every 4 weeks. Nucala may decrease airway inflammation that may trigger severe asthma attacks. Nucala targets eosinophils, one source of inflammation, so it treats more than just the symptoms of severe asthma. Nucala is not a steroid, but when added to the asthma medication, it helps to reduce the use of steroids like prednisone.

The most common side effects of Nucala include headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and weakness (fatigue), etc.

9. Singulair

Singulair by its revenue is the ninth best-selling asthma drug manufactured by Merck & Co., Inc. . In FY 2018 it had total global sales of USD 0.708 billion. Singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12months of age and older. Singulair does not contain a steroid.

Singulair is used to:

  • Prevent asthma attacks and for the long-term treatment of asthma in adults and children ages 12 months and older
  • Not to take Singulair if one need relief right away for a sudden asthma attack.
  • Prevent exercise-induced asthma in people 6 years of age and older.
  • Helps to control the symptoms of allergic rhinitis (sneezing, stuffy nose, runny nose, itching of the nose).

10. Fasenra

Fasenra by its revenue is the tenth best-selling asthma drug manufactured by AstraZeneca PLC. In FY 2018 it had total global sales of USD 0.297 billion. Fasenra is designed to target and remove eosinophils, a key cause of asthma. It can help improve breathing and prevent attacks. FASENRA is an add-on maintenance treatment for patients aged 12 and older with severe eosinophilic asthma. FASENRA is not an inhaler or a steroid. FASENRA is an injection given by a healthcare provider one dose every 8 weeks after the first 2 months.

Related Pharmaceutical Industry Articles

1. World's Top Selling Pharmaceutical Drugs and Manufacturers by Sales

2. Top 6 Therapeutic Companies to Look out for Acute Renal Failure (Acute Kidney Injury)

3. Top 10 Oncology Pharma Companies in the World

4. Top 10 Antidiabetics Pharma Companies in the World

Contact Us for Custom Market Research Solutions

 

MarketResearchReports.com Newsletter Subscription

Clients Who Trust Us

Market Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected